Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF Mutant Metastatic Colorectal Cancer Patients

PURPOSE: BRAF mutant metastatic colorectal cancer (mCRC) forms an aggressive subset of colorectal cancer with minimal response to selective RAF inhibitors. Preclinical data show that reactivation of epidermal growth factor receptor (EGFR) signaling occurs in colorectal tumor cells treated with RAF i...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Cancer Res
Prif Awduron: Yaeger, Rona, Cercek, Andrea, O'Reilly, Eileen M., Reidy, Diane L., Kemeny, Nancy, Wolinsky, Tamar, Capanu, Marinela, Gollub, Marc J., Rosen, Neal, Berger, Michael F., Lacouture, Mario E., Vakiani, Efsevia, Saltz, Leonard
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546416/
https://ncbi.nlm.nih.gov/pubmed/25589621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2779
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg